Abstract
Atazanavir is the most recently introduced protease inhibitor for the suppression of the anti-human immunodefficiency virus. A selective reversed-phase liquid chromatographic assay for this drug in human plasma has been developed and validated. Atazanavir was isolated from a 500 μL plasma sample using liquid-liquid extraction with dichloromethane. After evaporation and reconstitution of the extract the sample was analysed using liquid chromatography and ultraviolet detection at 280 nm. In the evaluated concentration range (44-4395 ng/mL atazanavir), intra-day precisions were ≤7% and inter-day precisions were ≤14%. Accuracies between 96 and 106% were found. The lower limit of quantification was 44 ng/mL with an intra-day precision of 7%, an inter-day precision of 14% and an accuracy of 87%. There was no interference from 32 tested potentially co-administrated drugs and metabolites. The usefulness of the assay was demonstrated for samples obtained from an HIV-infected patient treated with atazanavir.
Original language | English |
---|---|
Pages (from-to) | 72-76 |
Number of pages | 5 |
Journal | Biomedical Chromatography |
Volume | 20 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2006 |
Externally published | Yes |
Keywords
- Atazanavir
- Liquid chromatography
- Liquid-liquid extraction
- Protease inhibitor
- TEA, triethylamine